Amarin Q4 Revenue Drops as Vascepa Sales Slip, EPS Loss Narrows on Cost Cuts
Amarin’s Q4 2025 revenue declined as Vascepa sales slipped, while adjusted EPS loss narrowed on the back of cost controls. Management plans to cut operating expenses and advance its late-stage pipeline program to drive future growth.
1. Q4 2025 Financial Results
Amarin posted a year-over-year drop in Q4 2025 revenue driven by lower prescriptions of its flagship medication Vascepa. The company narrowed its adjusted EPS loss compared with the prior-year quarter through expense discipline.
2. Cost Reduction and Outlook
During the earnings call, management detailed targeted reductions in SG&A and R&D spending aimed at improving margins. Executives reiterated efforts to achieve sustainable operating leverage and reiterated guidance for a leaner cost structure in 2026.
3. Pipeline Advancement
Amarin emphasized progress on its late-stage clinical development program, signalling plans to initiate upcoming trials and seek regulatory meetings. Leadership views pipeline momentum as essential to offset mature Vascepa revenues and support long-term shareholder value.